Drug Trial Radar · NCT05579730
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
Last checked: Nov 19, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
188
Actual
Start
Oct 12, 2022
Primary completion
Jul 22, 2023
Study completion Jul 22, 2023
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Oct 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:
Conditions
- Allergic Conjunctivitis
Interventions
Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%Drug
combination ophthalmic solution
Brimonidine Tartrate 0.025%Drug
ophthalmic Solution
Ketotifen Fumarate 0.035%Drug
ophthalmic Solution
VehicleDrug
ophthalmic Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular ItchingTime frame: Assessed at Visit 4b on day 1 (duration of action CAC at 8 hours post-instillation of study medication) and Visit 5 on day 15 (onset of action CAC at 15 minutes post-instillation of study medication).
- Conjunctival RednessTime frame: Assessed at Visit 4b on day 1 (duration of action CAC at 8 hours post-instillation of study medication) and Visit 5 on day 15 (onset of action CAC at 15 minutes post-instillation of study medication).
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
103
Phoenix, Arizona
101
Andover, Massachusetts
102
Memphis, Tennessee
114
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.